Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05739734

Safety of CRIS100 on Treatment Spinal Cord Injury

The goal of this clinical trial is to test CRIS100 treatment in participants with acute thoracic spinal cord injury. The main questions it aims to answer are:

* safety of CRIS100 * efficacy of CRIS100

Participants will receive 100 mcg CRIS100 in the epicenter of the spinal injury, within 72 hours of the trauma.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

About this study

Participants with complete spinal cord injury between T2 and T10 (ASIA A, according to ISNCSCI, 2019 revision) and:

  • occurred less than 72 hours ago
  • with surgical indication
  • bulbocavernous reflex present
  • who can receive treatment with CRIS100 within 72 hours after the trauma (preferably within 24 hours)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signature of the Free and Informed Consent Term by the participant or legal guardian
  • Age between 18 and 70 years old;
  • Thoracic spinal cord injury between T2 and T10, with surgical indication, occurred less than 72 hours before surgery;
  • Presence of bulbo cavernosum reflex;
  • Patients with a lesion classified as ASIA A according to the ISNCSCI (2019 revision);

Exclusion criteria

  • Absence of bulbocavernous reflex up to 72 hours after the trauma.
  • Presence of severe brain trauma.
  • Patients with lesions above T2 or below T10.
  • More than one site of spinal cord injury.
  • History of alcohol or illicit drug abuse, as defined by DSM 5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition or later).
  • Patients who need permanent mechanical respiratory support.
  • Polytraumatized patients who, in the investigator's assessment, compromise the neurological evolution.
  • Neurological diseases or functional dependence of any etiology prior to the trauma.
  • Any other comorbidity that, at the discretion of the investigator, makes it impossible to include the patient in the study.

Treatment and study plan

CRIS100

Drug

local application of CRIS100

Primary outcomes

  1. Serious adverse events (SAE)

    Time frame: 6 months

    Possible, probable, or definitely CRIS 100-related SAE

  2. Anti-drug antibodies (ADA)

    Time frame: 6 months

    Developing anti-CRIS100 antibodies

  3. Liver function

    Time frame: 6 months

    Liver enzyme values more than 2 times higher than the upper limit of normal.

  4. Kidney function

    Time frame: 6 months

    Plasma urea and/or creatinine concentration above 2 times the upper limit of normality

  5. White blood cell (WBC)

    Time frame: 6 months

    Increase in WBC count greater than 20% of the upper limit of normal

  6. Hemoglobin

    Time frame: 6 months

    Decrease in hemoglobin concentration greater than 20% of the lower limit of normal

  7. Imaging exams

    Time frame: 6 months

    Changes in spinal cord imaging (MRI or CT) that indicate worsening of the primary lesion

Secondary outcomes

  1. Efficacy of CRIS100

    Time frame: 6 months

    Improvement in AIS grade of one or more levels according to ISNCSCI.

Study contacts

Contact information is provided by the study sponsor or research team.

Jorge B Afiune, MD

CONTACT

[email protected]

+55 11 98364 5551

Patricia C Bombarda, Post Graduate

CONTACT

[email protected]

+551146135119

Sponsors and collaborators

Lead sponsor

Cristália Produtos Químicos Farmacêuticos Ltda.

Industry

Registry information

Official study title

Clinical Safety Study of the Application of CRIS100 in Participants With Acute Spinal Cord Injury

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Feb 22, 2023
Registry last updated
Feb 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.